Wikisage, the free encyclopedia of the second generation, is digital heritage
Alprazolam: Difference between revisions
m (Rfz) |
m (GABAA_receptor_positive_allosteric_modulators) |
||
| (8 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
Alprazolam and alprazolam-XR carry the same general risk of withdrawal as other benzodiazepines. | Alprazolam and alprazolam-XR carry the same general risk of withdrawal as other benzodiazepines. | ||
There are also encouraging case reports and case series with the use of other antiseizure medications to help alleviate symptoms of benzodiazepine withdrawal. There are 3 case reports suggesting that [[valproate]] may be effective for the treatment of sedative-hypnotic withdrawal, but a double-blind, placebo-controlled study failed to replicate the results. | There are also encouraging case reports and case series with the use of other antiseizure medications to help alleviate symptoms of benzodiazepine withdrawal. There are 3 case reports suggesting that [[valproate]] may be effective for the treatment of sedative-hypnotic withdrawal, but a double-blind, placebo-controlled study failed to replicate the results. | ||
When gabapentin, an antiseizure medication with high affinity for voltage-gated calcium channels was added to a structured withdrawal regimen in patients with benzodiazepines use disorder for rapid inpatient withdrawal (less than a week); patients experienced minimal discomfort and the added benefit of reduced cravings for benzodiazepines. | When [[Gabapentin_enacarbil|gabapentin]], an antiseizure medication with high affinity for voltage-gated calcium channels was added to a structured withdrawal regimen in patients with benzodiazepines use disorder for rapid inpatient withdrawal (less than a week); patients experienced minimal discomfort and the added benefit of reduced cravings for benzodiazepines. | ||
<ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846112/pdf/nihms947341.pdf A review of Alprazolam use, misuse, and withdrawal J Addict Med. 12(1) 4-10]</ref> | <ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846112/pdf/nihms947341.pdf A review of Alprazolam use, misuse, and withdrawal J. Addict Med. 12(1) 4-10]</ref> | ||
==Links== | |||
Conn D et al 2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067147/pdf/cgj-8-116.pdf Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title] | |||
Navy, Hilary et al.2018 | |||
[https://www.ingentaconnect.com/content/ascp/tcp/2018/00000033/00000012/art00007;jsessionid=9ug0wpe34rbx.x-ic-live-03 Clinical Pharmacist Intervention to Engage Older Adults in Reducing Use of Alprazolam] | |||
===[[Epilepsy|epilepsia]]=== | |||
French Jacqueline A (2019) | |||
[https://onlinelibrary.wiley.com/doi/full/10.1111/epi.16279 Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants] epilepsia: | |||
{{Wikidata|Q319877}} | |||
{{refs}} | |||
[[category:GABAA receptor positive allosteric modulators]] | |||
Latest revision as of 14:10, 5 November 2024
This benzodiazepine [1] [2] produce reinforcing effects indicating misuse liability in subjects with histories of drug misuse. Alprazolam’s misuse potential stems from its unique pharmacokinetic properties of rapid absorption, low lipophilicity, and short half-life Alprazolam and alprazolam-XR carry the same general risk of withdrawal as other benzodiazepines. There are also encouraging case reports and case series with the use of other antiseizure medications to help alleviate symptoms of benzodiazepine withdrawal. There are 3 case reports suggesting that valproate may be effective for the treatment of sedative-hypnotic withdrawal, but a double-blind, placebo-controlled study failed to replicate the results. When gabapentin, an antiseizure medication with high affinity for voltage-gated calcium channels was added to a structured withdrawal regimen in patients with benzodiazepines use disorder for rapid inpatient withdrawal (less than a week); patients experienced minimal discomfort and the added benefit of reduced cravings for benzodiazepines. [3]
Links
Conn D et al 2020 Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title
Navy, Hilary et al.2018 Clinical Pharmacist Intervention to Engage Older Adults in Reducing Use of Alprazolam
epilepsia
French Jacqueline A (2019)
Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants epilepsia:
Interwiki via Wikidata
| References: |